Dan Duda, PhD, DMD

Duda Lab: Dan G. Duda, PhD, DMD

Research topics include: tumor microenvironment, metastatic progression, resistance to targeted therapy, radiation and immunotherapy, and biomarkers of response.

Overview

Dan G. Duda, PhD, DMD

Director,
Translational Research in GI Radiation Oncology,
Massachusetts General Hospital

Investigator,
Edwin L. Steele Laboratories for Tumor Biology,
Massachusetts General Hospital Research Institute

Associate Professor,
Harvard Medical School


Overview

Dan G. Duda obtained his DMD from the University of Medicine Iasi, Romania in 1993, and earned his PhD in Medical Sciences (Surgery) from Tohoku University Graduate School of Medicine, Sendai, Japan in 2001.

After graduation, he pursued a postdoctoral fellowship in the Steele Laboratories for Tumor Biology in the Department of Radiation Oncology at Massachusetts General Hospital and Harvard Medical School in Boston.

He became a Junior Faculty member (Instructor) in 2004, and then rose through the ranks to Investigator at Massachusetts General Hospital Research Institute in 2016 and Associate Professor of Tumor Biology (Radiation Oncology) at Harvard Medical School in 2012.

In 2016, he was also appointed as the Director of Translational Research in GI Radiation Oncology. He has been active internationally, and is currently serving as the Head of the Cancer Research Section (since 2013) and Secretary General (since 2015) of the International Association of Surgeons, Gastroenterologists and Oncologists (IASGO). He has also been serving as a panel member for multiple scientific expert/grant review meetings worldwide since 2009.

His current research efforts focus on the role of the interactions between the tumor microenvironment (tumor-associated vessels, fibrosis), the distant stroma (inflammatory cells), and cancer cells in mediating tumor progression and resistance to treatment.

The goal is to identify and validate targets for combination therapy (with radiation and immunotherapy) in preclinical studies, and conduct in parallel studies of biomarkers of response in correlative clinical studies.

His research is currently supported by grants from the US National Cancer Institute, Massachusetts General Hospital ECOR, Andrew L. Warshaw, MD, Institute for Pancreatic Cancer and The Samuel Singer Brown Fund for Pancreatic Ductal Adenocarcinoma Research, as well as by partnerships with Industry (Merrimack Pharma, Bayer Pharma, Bristol Myers Squibb Pharma and Leap Tx Pharma).

He has authored over 170 publications so far, of which over 100 are original reports, including articles in Nature, Nature Genetics, Nature Medicine, Cell, Cancer Cell, Science Translational Medicine, PNAS, JNCI, and Journal of Clinical Oncology. He has been invited to present his results at over 130 local, national and international meetings, including at grand rounds, as plenary speaker and as keynote speaker.

For his work, Dr. Duda received several awards, including from the American Association for Cancer Research, Cancer Research Institute, IASGO, Massachusetts General Hospital and the Granara-Skerry Trust for Cancer Research. He is an Honorary Member of the Academy of Medical Sciences of Romania since 2012. (See full CV)

Group Members

Dan G. Duda, PhD, DMD
Principal Investigator

Group Members

  • Daniel Schanne, MD, Postdoctoral Fellow
  • Kohei Shigeta, MD, PhD, Postdoctoral Fellow
  • Suji Kitahara, DDS, PhD, Postdoctoral Fellow
  • Shuichi Aoki, MD, PhD, Postdoctoral Fellow
  • Sergey Kozin, PhD, Research Associate
  • Rakesh R. Ramjiawan, MSc, Graduate Student
  • Nisha Gupta, MSc, Graduate Student
  • Anna Khachatryan, BS, Senior Technologist

Publications

Contact

Contact Us

Duda Laboratory

Edwin L. Steele Laboratory for Tumor Biology

Back to Top